Candel Therapeutics highlighted recent successes across the Company’s immunotherapy portfolio and provided updates on multiple upcoming milestones. 2024 Anticipated Data Readouts and Key Catalysts: Candel plans to announce 6 anticipated readouts across its 3 platforms in 2024, which include novel clinical and biomarker data in lung cancer, pancreatic cancer, brain cancer and a potentially registrational phase 3 clinical trial in prostate cancer. Phase 2 topline overall survival data for CAN-2409 in NSCLC expected in Q2 2024; Phase 2 updated overall survival data for CAN-2409 in borderline resectable pancreatic cancer expected in Q2 2024; New preclinical data on the second drug candidate from the enLIGHTEN(TM) Discovery Platform expected by Q3 2024; Phase 1 data for CAN-3110 in recurrent high-grade glioma expected in 2H 2024 for the multiple injection cohort; Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer expected in Q4 2024; Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer expected in Q4 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CADL:
- Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
- TScan Therapeutics appoints Amello as Chief Financial Officer
- Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
- Candel Therapeutics receives FDA fast track designation for CAN-2409
